Serial No: 10/618,977 PATENT

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-34. (Cancelled).

RECEIVED CENTRAL FAX CENTER FEB 0 1 2007

Please enter the following new claims.

1 35. (New) A method of delivering a lipophilic bioactive material to an interior wall of a body vessel from an implantable medical device having an 2 3 expandable balloon with the lipophilic bioactive material on an outer surface of the balloon, the method comprising the steps of: inserting the balloon into a body vessel, the balloon being free of: a 5 coating atop the bioactive material, a time-release layer, a containment 6 7 material and a containment layer; advancing the balloon within the body vessel to a treatment site 8 9 within the body vessel; inflating the balloon at the treatment site to contact the bioactive 10 11 material with an inner wall of the body vessel; 12 maintaining the bioactive material on the outer surface of the inflated balloon in contact with the inner wall of the body vessel while the 13 balloon is inflated: 14 deflating the balloon after contacting the bioactive material with the 15 16 inner wall of the body vessel; and 17 removing the deflated balloon from the body vessel.

- 2 -

The method of claim 35, wherein the balloon is inflated at the

36. (New)

1

2

treatment site with an inflation time of up to about one minute.

 byce 0/11 a bood of 2010200 3:40:21 PM [Eastern Standard Time] as Section (Section 5/122 and 5

- 1 37. (New) The method of claim 35, wherein the bloactive material
- 2 comprises paclitaxel or a paclitaxel derivative.
- 1 38. (New) The method of claim 37, wherein the bioactive material further
- 2 comprises a diagnostic agent.
- 1 39. (New) The method of claim 35, wherein the body vessel is a blood
- 2 vessel.
- 1 40. (New) The method of claim 39, wherein the body vessel is a coronary
- 2 artery.
- 1 41. (New) The method of claim 35, wherein the implantable medical
- 2 device includes a total of about 5 to about 500 micrograms of the lipophilic
- 3 bioactive material on the outer surface of the balloon prior to inserting the
- 4 medical device into the body vessel.
- 1 42. (New) The method of claim 35, wherein the method is performed
- 2 without implanting a stent within the body vessel.
- 1 43. (New) The method of claim 35, wherein the balloon comprises a
- 2 material selected from the group consisting of: a polyamide, polypropylene,
- 3 polyether block amide and polyethylene.
- 1 44. (New) The method of claim 35, wherein the implantable medical
- 2 device is a balloon catheter coated with a single layer of the lipophilic bioactive
- 3 material on the balloon, the single layer consisting essentially of about 5 to
- 4 about 500 micrograms of paclitaxel or a paclitaxel derivative deposited on the
- 5 outer surface of the expandable balloon.

1

2	material is transferred from the outer surface of the inflated balloon to the	
3	inner wall of the body vessel while contacting the outer surface of the inflated	
4	balloon with the inner wall of the body vessel.	
1	46. (New) The method of claim 35, wherein the implantable medical	
2	device is a balloon catheter having an expandable balloon with about 0.2 to	
3	about 20 micrograms of paclitaxel or a paclitaxel derivative deposited per mm²	!
4	of the outer surface of the expandable balloon and a total of about 5 to about	
5	500 micrograms of the paclitaxel or the paclitaxel derivative deposited on the	
6	outer surface of the expandable balloon; and wherein the method further	
7	includes at least one of:	
8	percutaneous insertion of the expandable balloon into a blood	
9	vessel;	
O	inflation of the balloon at the treatment site with an inflation time of	
1	up to about one minute to contact the paclitaxel or the paclitaxel derivative	
2	with the inner wall of the body vessel; or	
3	maintaining the outer surface of the inflated balloon in contact with	
4	the inner wall of the body vessel for up to about 20 minutes.	
1	47. (New) The method of claim 35, wherein	
2	the implantable medical device is a balloon catheter having an	
3	expandable balloon with a total of about 5 to about 500 micrograms of paclitate	kel
4	or a paclitaxel derivative deposited on the outer surface of the expandable	
5	balloon;	
6	the expandable balloon is percutaneously inserted into a blood	
7	vessel;	
8	the balloon is inflated at the treatment site with an inflation time of	
9	up to about one minute to contact the paclitaxel or paclitaxel derivative with	
0	the inner wall of the body vessel; and	

45. (New) The method of claim 35, wherein the lipophilic bioactive

 byce 8/11 * BCAD VI 5/1/5003 3:40:21 PM [Eastern Standard Time] * SVR:USPTO-EFTRE-5/123 * DNIS:2738300 * CSID:8123300040 * DURATION (mm-ss):07-08

 Serial No. 10/618,73300040 * DURATION (mm-ss):07-08

- the outer surface of the inflated balloon is maintained in contact with the inner wall of the body vessel for up to about 20 minutes.
- 1 48. (New) The method of claim 35, wherein the implantable medical
- 2 device is a balloon catheter having an expandable balloon with a total of about
- 3 0.2 to about 20 micrograms of paclitaxel or a paclitaxel derivative per mm² of
- 4 the outer surface of the expandable balloon before inserting the balloon into
- 5 the body vessel.